Statin Use in HIV: Check Vitamin D Levels

JANUARY 09, 2017
Jeannette Y. Wick, RPh, MBA, FASCP

Approximately one-third of the US population is at risk of or already deficient in vitamin D, defined as a serum 25-hydroxyvitamin D level <50 nmol/L. Low 25-hydroxyvitamin D is prevalent in the HIV-infected population, and may be associated with increased risk of disease progression.
 
A study published in a recent issue of the Journal of Acquired Immune Deficiency Syndromes demonstrates that low baseline vitamin D deficiency may decrease the effectiveness of rosuvastatin in adults with HIV.
 
The research group analyzed serum 25-hydroxyvitamin D concentrations from SATURN-HIV, a randomized placebo, controlled trial evaluating the effects of rosuvastatin in adults with HIV.  They investigated whether rosuvastatin affected serum vitamin D levels over time, and if vitamin D status modified rosuvastatin’s effects.
 
They compared 25-hydroxyvitamin D levels at baseline and at the end of the study period between the placebo and rosuvastatin groups. Changes in vitamin D levels, regardless of baseline status, were not significant, suggesting that rosuvastatin does not have an effect on vitamin D. 
 
However, baseline vitamin D deficiency (defined in this study as <20 ng/mL) negatively impacted rosuvastatin’s beneficial effects on both cardiovascular and immune-activation endpoints, showing either weakened or unapparent effectiveness overall. This was seen in changes in LDL-cholesterol, lipoprotein-associated phospholipase A2, and common carotid artery intimal media thickness. The researchers also noted changes in the proportion of patrolling monocytes, a subset of monocytes that patrol healthy tissues by long-range crawling on the resting endothelium.
 
Findings from this analysis suggest that rosuvastatin administration does not improve vitamin D levels. However, individuals with baseline vitamin D deficiencies may experience diminished rosuvastatin effectiveness.
 
The researchers concluded that vitamin D supplementation may be necessary when initiating statin therapy in HIV patients who are deficient at baseline. 
 
Reference

Hileman C, Tangpricha V, Sattar A, McComsey G. Baseline vitamin D deficiency decreases the effectiveness of statins in HIV-infected adults on antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2016; doi:10.1097/qai.0000000000001281.
 

SHARE THIS SHARE THIS
81

A Fast, Easy Way to Inform Parents About Vaccinations

Officials with the Centers for Disease Control and Prevention have prepared an informational video on this topic.

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.